Phenotypic variations and new mutations in JAK2 V617F–negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

This publication has 27 references indexed in Scilit:

• The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
  Blood, 2007
• JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
  New England Journal of Medicine, 2007
• Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
  Blood, 2006
• MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
  Blood, 2006
• MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
  PLoS Medicine, 2006
• The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2^V617F in polycythemia vera
  Cancer, 2005
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
  Blood, 2005
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
  Published by Elsevier ,2005
• A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders
  New England Journal of Medicine, 2005
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
  Nature, 2005